Advanced search
Publication Cover
Journal of Receptors and Signal Transduction Volume 39, 2019 - Issue 4
Submit an article Journal homepage
73
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints

Tahereh DamghaniMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ;School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; View further author information
,
Korosh MashayekhMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; View further author information
,
Somayeh PirhadiMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-7443-8078View further author information
ORCID Icon,
Omidreza FiruziMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; View further author information
,
Shahrzad SharifiMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; View further author information
,
Najmeh EdrakiMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; View further author information
,
Mehdi KhoshneviszadehMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ;School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; View further author information
&
Mohammad Sadegh AvestanDepartment of Chemistry, University of Cincinnati, Cincinnati, OH, USAView further author information
 show all
Pages 295-303 | Received 10 Apr 2019, Accepted 28 Sep 2019, Published online: 28 Oct 2019

References

  • Tarver T. Cancer facts and figures 2012. Atlanta (GA): American Cancer Society, 2012; p. 66.
  • Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341–358.
  • Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89.
  • Demkova L, Kucerova L. Role of the HGF/c-MET tyrosine kinase inhibitors in metastatic melanoma. Mol Cancer. 2018;17(1):26.
  • Jeon H-M, Lee J. MET: roles in epithelial-mesenchymal transition and cancer stemness. Ann Transl Med. 2017;5(1):5.
  • Planchard D. Have we really MET a new target? J Clin Oncol. 2018;36(31):3069–3071.
  • Helena AY, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
  • Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342–6363.
  • Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9(6):314.
  • Lolkema MP, Bohets HH, Arkenau H-T, et al. The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species-specific insoluble metabolite formation. Clin Cancer Res. 2015;21(10):2297.
  • Ugolini A, Kenigsberg M, Rak A, et al. Discovery and pharmacokinetic and pharmacological properties of the potent and selective MET kinase inhibitor 1-{6-[6-(4-fluorophenyl)-[1, 2, 4] triazolo [4, 3-b] pyridazin-3-ylsulfanyl] benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl) urea (SAR125844). J Med Chem. 2016;59(15):7066–7074.
  • Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Therap. 2011;10(12):2298.
  • Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1535–1553.
  • Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 2014;57(11):4427–4453.
  • Ghasemi JB, Meftahi N, Pirhadi S, et al. Docking and pharmacophore‐based alignment comparative molecular field analysis three‐dimensional quantitative structure–activity relationship analysis of dihydrofolate reductase inhibitors by linear and nonlinear calibration methods. J Chemometrics. 2013;27(10):287–296.
  • Wang W, Xu S, Duan Y, et al. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors. Eur J Med Chem. 2018;145:315–327.
  • https://www.proteinatlas.org/ENSG00000105976-MET/cell.
  • Yap CW. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem. 2011;32(7):1466–1474.
  • Ambure P, Aher RB, Gajewicz A, et al. “NanoBRIDGES” software: open access tools to perform QSAR and nano-QSAR modeling. Chemometr Intell Lab Syst. 2015;147:1–13.
  • Nunes CA, Freitas MP, Pinheiro ACM, et al. Chemoface: a novel free user-friendly interface for chemometrics. J Braz Chem Soc. 2012;23(11):2003–2010.
  • Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727–748.
  • Contrera JF, MacLaughlin P, Hall LH, et al. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr Drug Discov Technol. 2005;2(2):55–67.
  • Todeschini R, Consonni V. Molecular descriptors for chemoinformatics. Volume I: alphabetical listing/Volume II: appendices, references, Volume 41. Hoboken, NJ: John Wiley & Sons; 2009.
  • Stanton DT, Jurs PC. Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies. Anal Chem. 1990;62(21):2323–2329.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.